{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.74","value":"16.2"},{"groupId":"OG001","spread":"1.02","value":"23.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"158"}],"units":"Participants"}],"title":"Dyspnoea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.59","value":"9.4"},{"groupId":"OG001","spread":"0.82","value":"11.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"title":"Pain in chest"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.69","value":"10.6"},{"groupId":"OG001","spread":"0.97","value":"12.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"title":"Pain in Arm or Shoulder"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.71","value":"12.5"},{"groupId":"OG001","spread":"1.01","value":"15.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"title":"Pain in Other Parts"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.63","value":"14.7"},{"groupId":"OG001","spread":"0.88","value":"23.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"title":"Coughing"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.35","value":"3.0"},{"groupId":"OG001","spread":"0.49","value":"6.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"title":"Sore Mouth"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.37","value":"4.1"},{"groupId":"OG001","spread":"0.52","value":"5.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"title":"Dysphagia"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.69","value":"9.7"},{"groupId":"OG001","spread":"0.96","value":"16.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"title":"Peripheral Neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.70","value":"6.8"},{"groupId":"OG001","spread":"0.95","value":"13.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"title":"Alopecia"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.18","value":"0.7"},{"groupId":"OG001","spread":"0.25","value":"1.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"title":"Haemoptysis"}],"denoms":[{"counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"description":"The EORTC QLQ-LC13 was used in conjunction with the EORTC QLQ-C30 and provided information on an additional 13 items specifically related to lung cancer. The lung cancer module incorporated one multi-item scale to assess dyspnea, and 9 single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. Items were scored on a 4-point Likert scale ranging from 1=\"not at all\" to 4=\"very much\". For the multi-item scale, the scores were averaged from the scores of the component items, transformed, and then analyzed on a 0 - 100 scale. For the single item scale, raw scores were transformed and analyzed on a 0-100 scale. A high score indicated a high level of symptoms The scores were analyzed using repeated measurement model for longitudinal data, including terms for visit, treatment, treatment by time interaction, strata and baseline score. Overall mean and standard error were obtained.","dispersionType":"Standard Error","groups":[{"description":"Ceritinib administered continuously through oral dosing at a dosage of 750 mg once daily in fasted state","id":"OG000","title":"Ceritinib"},{"description":"Pemetrexed plus cisplatin or carboplatin (based on Investigator's choice) for 4 cycles (Induction) followed by pemetrexed as single agent (Maintenance)","id":"OG001","title":"Chemotherapy"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set (FAS) consisted of all patients to whom study treatment had been assigned by randomization. Participants with a baseline assessment for at least one of the domain scores","reportingStatus":"POSTED","timeFrame":"Screening, treatment phase (Cycles 2, 3 then every 2nd cycle until Month 33; after Month 33, every 9 or 12 weeks, end of treatment); follow-up phase (Every 6 weeks until Month 33; after Month 33 every 9 or 12 weeks) up to approximately 120 months","title":"Least Squares Mean Scores on the EORTC QLQ- LC13","type":"SECONDARY","unitOfMeasure":"Score on a scale"}